Tvardi Therapeutics
TVRDTvardi Therapeutics is a clinical-stage biopharmaceutical company developing novel, oral, small molecule therapies that target the Signal Transducer and Activator of Transcription 3 (STAT3) protein.
Earnings
Next report
Date not yet announcedCompetitors
Profile
Tvardi Therapeutics is a clinical-stage biopharmaceutical company developing novel, oral, small molecule therapies that target the Signal Transducer and Activator of Transcription 3 (STAT3) protein. The company focuses on treating inflammatory and proliferative diseases by directly inhibiting the canonical STAT3 pathway to modulate immune dysregulation and cellular survival. Their platform is designed to block disease-driving transcription without impairing essential mitochondrial functions.
Clinical-stage developer of first-in-class STAT3 inhibitors with Orphan Drug and Fast-Track designations for lead assets.
FAQ
- What is Tvardi Therapeutics's market cap?
- Tvardi Therapeutics (TVRD) has a market capitalization of $18.8M and trades on NASDAQ.
- Who are Tvardi Therapeutics's competitors?
- Tvardi Therapeutics's key competitors include Kymera Therapeutics, Rein Therapeutics, Inc. Common Stock, Instil Bio, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Where is Tvardi Therapeutics headquartered?
- Tvardi Therapeutics is headquartered in United States of America. It has been publicly traded since 2025.